MIR873

Summary

MIR873 (microRNA 873, HGNC:33663) is a microRNA gene on chromosome 9p21.1.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 100126316 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:33663
Approved symbol	MIR873
Name	microRNA 873
Location	9p21.1
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-873
Ensembl gene	ENSG00000215939
Ensembl biotype	miRNA
OMIM	616137
Entrez	100126316
RNAcentral	URS0000209F04 — miRNA, 77 nt, 53 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000401120

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000401120 — 1 exons

Exon	Start	End
ENSE00001546464	28888879	28888955

Expression profiles

Bgee: expression breadth broad, 28 present calls, max score 79.38.

Top tissues by expression

28 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	79.38	gold quality
blood	UBERON:0000178	78.61	gold quality
heart	UBERON:0000948	77.60	gold quality
kidney	UBERON:0002113	75.76	gold quality
intestine	UBERON:0000160	75.53	gold quality
stomach	UBERON:0000945	75.45	gold quality
heart left ventricle	UBERON:0002084	71.82	gold quality
prefrontal cortex	UBERON:0000451	69.54	gold quality
endometrium	UBERON:0001295	67.76	gold quality
uterus	UBERON:0000995	67.74	gold quality
body of stomach	UBERON:0001161	67.71	gold quality
tibial artery	UBERON:0007610	66.86	gold quality
urinary bladder	UBERON:0001255	66.84	gold quality
transverse colon	UBERON:0001157	66.32	gold quality
muscle layer of sigmoid colon	UBERON:0035805	66.08	gold quality
subcutaneous adipose tissue	UBERON:0002190	64.46	gold quality
corpus callosum	UBERON:0002336	63.72	gold quality
putamen	UBERON:0001874	62.81	gold quality
left lobe of thyroid gland	UBERON:0001120	62.39	gold quality
esophagus mucosa	UBERON:0002469	61.78	gold quality
right frontal lobe	UBERON:0002810	60.34	gold quality
right hemisphere of cerebellum	UBERON:0014890	59.48	gold quality
thyroid gland	UBERON:0002046	59.12	gold quality
pituitary gland	UBERON:0000007	57.98	gold quality
liver	UBERON:0002107	57.98	gold quality
tibial nerve	UBERON:0001323	57.55	gold quality
right testis	UBERON:0004534	45.61	gold quality
left testis	UBERON:0004533	45.36	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.33

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• Mir-873 inhibits ESR1 activity and cell growth via targeting CDK3. (PMID:25531331)
• observed that microRNA-873 (miR-873) was expressed at low levels in GBM and that the overexpression of miR-873 dramatically reduced the cell proliferation, migration, and invasion of GBM cells (PMID:25670861)
• these data suggest that miR873 might be a potential marker for cisplatin resistance in glioma and a promising sensitizer in cisplatin treatment. (PMID:26323558)
• There is a miR-873 binding region in the ABCB1 3’-UTr. MDR1 expression was downregulated after transfection with miR-873 and upregulated after transfection with anti-miR-873 at mRNA and protein levels. miR-873 increased the sensitivity to cisplatin and paclitaxel in OVCAR3 and A2780. Intratumoral administration of miR-873 enhanced the efficacy of cisplatin in inhibiting tumor growth in ovarian cancer in mouse xenografts. (PMID:26850595)
• miR-873 expression is upregulated in congenital heart disease serum samples. (PMID:28583401)
• miR-873 expression was significantly up-regulated in patients with SLE, and its expression was positively associated with the disease severity (PMID:28837808)
• Low miR873 expression is associated with colorectal cancer. (PMID:29328486)
• HuR facilitated lung cancer stemness dependent on CDK3 expression. miR-873 or miR-125a-3p level was negatively correlated with HuR and CDK3 expression levels in lung cancer tissues. HuR facilitates lung cancer stemness via regulating miR-873/CDK3 and miR-125a-3p/CDK3 axis. (PMID:29344850)
• In this report, it was found for the first time that GAS5 could inhibit HIV-1 replication. Interestingly, using bioinformatics analyses (with Genomica and starBase.v2.0), GAS5 was found to potentially interact with miR-873. It was further verified that GAS5 could suppress miR-873. Moreover, miR-873 could promote HIV-1 replication. (PMID:29620929)
• that suppression of TRIM25 expression by high levels of miR-873 dictates metastasis associated protein 1 protein upregulation in hepatocellular carcinoma (PMID:29654742)
• miRNA-873 promoted Hepatocellular Carcinoma progression by targeting TSLC1. (PMID:29734164)
• Our results revealed that miR-873 was significantly underexpressed in esophageal cancer tissues and cell lines. (PMID:29890466)
• The inhibition of miR-873 increased gefitinib resistance of NSCLC cells via the upregulation of GLI1. These results indicate that miR-873-GLI1 signaling is involved in gefitinib resistance in NSCLC. (PMID:30126075)
• that miR-873-5p suppressed cell migration, invasion and epithelial-mesenchymal transition in colorectal cancer via targeting ZEB1 (PMID:30455125)
• MiR-873 inhibited PD-L1 expression through directly binding to its 3’-untranslated region (UTR), and miR-873 attenuated the stemness and chemoresistance of breast cancer cells which was dependent on PD-L1 and the downstream PI3K/Akt and ERK1/2 signaling. (PMID:30803931)
• miR-873-5p inhibits the progression of colon cancer via repression of tumor suppressor candidate 3/AKT signaling. (PMID:31039290)
• These results demonstrated that miR873 may serve tumoursuppressive roles in the progression of thyroid cancer (TC), and its suppressive effects could be mediated by the inhibition of ZEB1. Therefore, miR873 may be a valuable therapeutic target in the management of patients with TC. (PMID:31257462)
• Long noncoding RNA DDX11-AS1 induced by YY1 accelerates colorectal cancer progression through targeting miR-873/CLDN7 axis. (PMID:31298324)
• Enhancing mitochondrial b-oxidation by relieving miR-873-5p repression on glycine N-methyltransferase may be an effective mechanism to reduce lipid burden in the liver. Thus, targeting miR-873-5p may be of wide applicability for NAFLD therapies. (PMID:31668391)
• STRA6 is down-regulated by miR-873 and plays an oncogenic role by activating Wnt/beta-catenin signalling in GC. (PMID:31694721)
• The crucial function of TDRG1-miR-873-5p-HDGF axis in human gastric cancer. (PMID:31726370)
• TNNT1, negatively regulated by miR-873, promotes the progression of colorectal cancer. (PMID:31830337)
• MiR-873, as a suppressor in cervical cancer, inhibits cells proliferation, invasion and migration via negatively regulating ULBP2. (PMID:31902110)
• Astrocyte-derived exosomes enriched with miR-873a-5p inhibit neuroinflammation via microglia phenotype modulation after traumatic brain injury. (PMID:32192523)
• The tumor-suppressive role of microRNA-873 in nasopharyngeal carcinoma correlates with downregulation of ZIC2 and inhibition of AKT signaling pathway. (PMID:32555352)
• TRIM29 inhibits miR-873-5P biogenesis via CYTOR to upregulate fibronectin 1 and promotes invasion of papillary thyroid cancer cells. (PMID:32994394)
• Mining miRNAs’ Expressions in Glioma Based on GEO Database and Their Effects on Biological Functions. (PMID:33102581)
• CircZKSCAN1 Suppresses Hepatocellular Carcinoma Tumorigenesis by Regulating miR-873-5p/Downregulation of Deleted in Liver Cancer 1. (PMID:33439397)
• LINC00941 promotes proliferation and metastasis of pancreatic adenocarcinoma by competitively binding miR-873-3p and thus upregulates ATXN2. (PMID:33660796)
• MiR-873-5p modulates progression of tongue squamous cell carcinoma via targeting SEC11A. (PMID:33675129)
• LncRNA FGD5-AS1 functions as an oncogene to upregulate GTPBP4 expression by sponging miR-873-5p in hepatocellular carcinoma. (PMID:34783233)
• Exposure to High-Altitude Environment Is Associated with Drug Transporters Change: microRNA-873-5p-Mediated Alteration of Function and Expression Levels of Drug Transporters under Hypoxia. (PMID:34844996)
• Hsa_circ_0058129 regulates papillary thyroid cancer development via miR-873-5p/follistatin-like 1 axis. (PMID:35373391)
• MicroRNA-873-5p suppresses cell malignant behaviors of thyroid cancer via targeting CXCL5 and regulating P53 pathway. (PMID:35486941)
• Circular RNA circTTBK2 facilitates non-small-cell lung cancer malignancy through the miR-873-5p/TEAD1/DERL1 axis. (PMID:35916080)
• Long non-coding RNA ERVK13-1 aggravates osteosarcoma through the involvement of microRNA-873-5p/KLF5 axis. (PMID:36272150)
• Silencing of UCA1 attenuates the ox-LDL-induced injury of human umbilical vein endothelial cells via miR-873-5p/MAPK8 axis. (PMID:36326096)
• Circ_MBNL3 Restrains Hepatocellular Carcinoma Progression by Sponging miR-873-5p to Release PHF2. (PMID:36380035)
• Circ_0005615 Regulates the Progression of Colorectal Cancer Through the miR-873-5p/FOSL2 Signaling Pathway. (PMID:36920708)
• ERVK13-1/miR-873-5p/GNMT Axis Promotes Metastatic Potential in Human Bladder Cancer though Sarcosine Production. (PMID:38003554)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir873b	ENSMUSG00000106425

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.